Key Takeaways
- The digital health platform posted adjusted EPS of $0.26, falling short of the $0.28 Wall Street consensus.
- Quarterly revenue reached $145.4 million, marking 5% growth year-over-year and marginally exceeding projections.
- Fiscal 2027 revenue guidance of $664–$676 million substantially missed the $697.4 million analyst consensus.
- Major firms including Jefferies, Wells Fargo, and KeyBanc downgraded their ratings on the stock post-earnings.
- Shares plummeted approximately 21% in Thursday’s premarket session, extending year-to-date losses to roughly 47%.
Shares of Doximity were changing hands near $18.45 during premarket hours Thursday — representing a steep decline of approximately 21% from Wednesday’s closing price of $23.39 — following the company’s underwhelming quarterly results and guidance that failed to meet Street expectations.
The physician-focused networking and telehealth company delivered adjusted earnings of $0.26 per share for the fiscal fourth quarter, falling short of the $0.28 consensus forecast. This compared unfavorably to the $0.36 per share the company generated in the year-ago quarter.
Quarterly revenue totaled $145.4 million, reflecting 5% year-over-year expansion and narrowly surpassing the $144 million Street estimate. However, the modest revenue beat proved insufficient to calm investor concerns about the company’s trajectory.
Adjusted EBITDA landed at $65.8 million for the period, representing a 6% decline from the prior-year quarter, with management attributing the margin pressure to elevated investments in AI infrastructure.
Chief Executive Officer Jeff Tangney highlighted robust platform engagement during the earnings conference call, emphasizing that more than 800,000 active prescribers utilized Doximity’s workflow solutions in the fourth quarter. “Approximately half of these healthcare providers leveraged our clinical AI capabilities last quarter, with prompts per user nearly doubling between January and April,” Tangney remarked.
Forward Outlook Disappoints Investors
The more significant challenge for shareholders centered on the company’s forward-looking statements. For fiscal year 2027 ending in March, Doximity projected revenue ranging from $664 million to $676 million — a substantial shortfall compared to the $697.4 million consensus among analysts.
Near-term guidance also underwhelmed. The company forecasted first-quarter revenue of $151 million to $152 million, trailing the $153.7 million that Wall Street anticipated.
Executives acknowledged that “near-term demand dynamics in the healthcare professional digital pharma advertising market remain challenged” and cited macroeconomic uncertainty alongside policy risks as factors constraining forward visibility. Leadership anticipates overall market expansion to remain subdued, likely tracking at or below 5% growth rates.
Adjusted EBITDA margin for the upcoming fiscal year is projected to approximate 49%, declining from prior-year levels, predominantly due to escalating AI computational expenses.
Wall Street Firms Slash Ratings
The quarterly results and guidance prompted immediate analyst downgrades. Jefferies lowered its rating from Buy to Hold while slashing its price objective from $51 to $19, citing limited transparency on pharmaceutical advertising budgets and mounting AI-related expenditures.
Wells Fargo adjusted its stance from Overweight to Equal Weight, establishing a new price target of $18. KeyBanc switched to Sector Weight, observing that potential customers are increasingly exploring AI-powered and more cost-effective alternatives to Doximity’s offerings.
Broader market conditions provided no cushion. The S&P 500 advanced 0.58% while the Nasdaq Composite climbed 1.20% Thursday, indicating the DOCS selloff was driven entirely by company-specific factors.
Shares currently trade approximately 69% below the 52-week peak of $76.51. During the 90-day period preceding the earnings release, analysts made zero upward EPS revisions while issuing 15 downward adjustments — evidence that sentiment had already deteriorated significantly.
The company separately disclosed a strategic partnership with Aledade, a value-based care organization, through which Doximity will integrate its clinical AI tools, including automated documentation and AI assistant capabilities, directly into Aledade’s healthcare systems.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
